Clot-busting drug benefits intermediate-risk patients with pulmonary embolism
The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing between 60,000 and 100,000 Americans each year. The most common cause of death is progressive failure of the heart's right ventricle, which sends blood to the lungs to pick up oxygen. Right ventricle failure leads to hemodynamic collapse, which means blood no longer circulates properly. Blood pressure suddenly drops or disappears altogether, and the risk of death is high.
Heparin is the current standard therapy for most patients, including a subgroup of patients that is said to have submassive or intermediate-risk pulmonary embolism: that is, they have normal blood pressure but dysfunction of the heart's right ventricle, which can be seen on an echocardiogram or CT scan. Blood tests also can help to identify these patients.
The Pulmonary Embolism Thrombolysis Study (PEITHO) tested the addition of a clot-busting (thrombolytic) drug, tenecteplase, to standard treatment with heparin. Tenecteplase dissolves blood clots rapidly but carries a known risk of bleeding in the brain. The double-blind study included 1,006 patients in 13 countries. They were randomized to heparin plus placebo or heparin plus tenecteplase.
The combined primary endpoint was death from any cause or circulatory system (hemodynamic) collapse after seven days. Hemodynamic collapse was defined as at least one of the following: needing CPR due to a loss of blood pressure; systolic blood pressure of less than 90 mm Hg or a drop of more than 40 mm Hg for at least 15 minutes; or the need for drugs called catecholamines, which boost circulation.
The primary endpoint was reduced by 56 percent in patients treated with tenecteplase and heparin, compared with the heparin-only group.
"In patients with intermediate-risk pulmonary embolism, thrombolytic treatment significantly reduced the primary endpoint," said Stavros Konstantinides, MD, PhD, professor for clinical trials at the Center for Thrombosis and Hemostasis, University of Mainz, Germany, and the study's co-principal investigator. "Overall, the study strongly supports the concept that risk stratification of patients makes sense and that these patients need something to prevent deterioration."
There was a significant reduction in hemodynamic collapse: it occurred in 1.6 percent of patients receiving tenecteplase versus 5 percent receiving placebo. Actual death rates were low and not significantly different between groups: 1.2 percent in the tenecteplase group versus 1.8 percent in the placebo group.
Major bleeding was significantly increased with tenecteplase: 6.3 vs. 1.5 percent in the placebo group. There were 10 hemorrhagic strokes in the tenecteplase group and one in the placebo group.
"This is more or less the rate that we have seen in previous thrombolytic trials," Dr. Konstantinides said. "Patients who were less than 75 years old had most of the benefit and a tendency toward fewer hemorrhagic strokes. Our future priorities are now to refine our risk stratification concept even further, to better identify those patients who will benefit most with less risk of bleeding. Also, the dose of the drug that we used could be lowered in older patients, and alternative methods of delivering thrombolytics could be explored."
More information: Dr. Konstantinides will present "Single-bolus Tenecteplase Plus Heparin Compared With Heparin Alone for Normotensive Patients With Acute Pulmonary Embolism Who Have Evidence of Right Ventricular Dysfunction and Myocardial Injury: The Pulmonary Embolism Thrombolysis (PEITHO) Study" on Monday, March 11, at 11:45 a.m., in Moscone Center, South, Esplanade Ballroom.
Provided by American College of Cardiology
- Clot-busting drug as effective as angioplasty Mar 12, 2013 | not rated yet | 0
- 'Clot-busters' no more effective than traditional therapy in treating lung blood clots May 16, 2011 | not rated yet | 0
- Tenecteplase drug bests standard treatment for certain strokes Mar 22, 2012 | not rated yet | 0
- Clot-busters safe for treating moderate pulmonary embolism Mar 27, 2012 | not rated yet | 0
- For embolism patients, clot-busting drug is worth risk Feb 21, 2013 | not rated yet | 0
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Assumptions of Griffith's fracture theory
1 hour ago Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
Current leading voltage or vice versa concept
3 hours ago Hello, I was wondering if there is a conceptual explanation for when current leads voltage or vice versa for capacitors or inductors with AC...
Angular Frequency of AC voltage
6 hours ago Hello, I am wondering, what is the physical interpretation of the angular frequency of AC voltage? I don't see the physicality of what the angle...
Modeling Rigid Body - Unsure about Euler angles and angular velocity
6 hours ago I'm modeling a single 3D rigid body in preparation for some more complicated modeling in order to gain a better understanding of Euler angles, the...
Function for a bullet's path
8 hours ago I've been mulling this over all weekend, and I've decided to get some help on this. The problem is writing a function to describe a bullet's path....
Elementary questions relating to Newton's laws of motion
9 hours ago i) If a wall breaks when it gets hit by a cannonball, did the wall exert an equal and opposite force on the cannonball? ii) Would the force...
- More from Physics Forums - Classical Physics
More news stories
Hospitals with the highest rates of cardiac arrests tend to have the poorest survival rates for those cases, new University of Michigan Health System research shows.
Cardiology 12 hours ago | not rated yet | 0
A clinical trial of 75 patients hospitalized with acute decompensated heart failure (ADHF) suggests that aggressive fluid and sodium restriction has no effect on weight loss or clinical stability at three days but was associated ...
Cardiology 12 hours ago | not rated yet | 0
National guidelines recommend that at-risk women be screened for elevated cholesterol levels to reduce their chances of developing cardiovascular disease. But who is 'at risk?' The results of a study by investigators ...
Cardiology 15 hours ago | not rated yet | 0
Researchers at Lund University in Sweden have mapped the significance of heredity for common forms of atherosclerotic disease. No studies have previously examined whether different forms of the disease share heredity.
Cardiology 16 hours ago | not rated yet | 0
(Medical Xpress)—Life-saving CPR has been a foundation of emergency medicine for more than a half century. But researchers at the University of Arizona College of Medicine-Phoenix are continuing to refine the procedure, ...
Cardiology 18 hours ago | not rated yet | 0
11 minutes ago | not rated yet | 0 |
11 minutes ago | not rated yet | 0
9 hours ago | 4.6 / 5 (12) | 4 |
4 hours ago | not rated yet | 0 |
12 hours ago | 4.8 / 5 (11) | 2 |
Salamanders' immune systems are key to their remarkable ability to regrow limbs, and could also underpin their ability to regenerate spinal cords, brain tissue and even parts of their hearts, scientists have ...
13 hours ago | 4.8 / 5 (6) | 2 |